Evolus Inc Director Karah Parschauer Sells 11,931 Shares
Karah Parschauer, a Director at Evolus Inc (NASDAQ:EOLS), has sold 11,931 shares of the company on January 30, 2024, according to a recent SEC Filing. The transaction was executed at a stock price of $13.14, resulting in a total sale amount of approximately $156,813.34.
Evolus Inc is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. Its principal product is Jeuveau, a proprietary 900 kDa purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Over the past year, the insider has sold a total of 11,931 shares and has not made any purchases of the stock. This latest transaction continues the trend observed over the past year, where there has been a total of 1 insider buy and 13 insider sells for Evolus Inc.
On the valuation front, Evolus Inc's shares were trading at $13.14 on the day of the insider's sale, giving the company a market capitalization of $776.882 million. The stock's price-to-GF-Value ratio stands at 0.99, indicating that it is Fairly Valued when compared to the GF Value of $13.33.
The GF Value is a proprietary intrinsic value estimate from GuruFocus, which is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, an adjustment factor based on the company's historical returns and growth, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
